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293 Two-year follow-up for lung function, muscle strength and
functional capacity in cystic ﬁbrosis
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The purpose of this study was to investigate the change in lung function, respiratory
and peripheral muscle strength, and functional capacity during two-year follow-up
period in patients with cystic ﬁbrosis followed by home respiratory physiotherapy
treatment.
Eight patients with cystic ﬁbrosis (16.63±3.93 years, FEV1= 63.38±19.75%)
participated in this study. Pulmonary function tests were performed. Respiratory
muscle strength (MIP and MEP) was measured using a mouth pressure device.
Quadriceps femoris strength was measured using a hand-held dynamometer. Func-
tional capacity was evaluated with 6-minute walk test (6MWT). Body mass index
(BMI) was calculated. Patients were followed by an individually applied respiratory
physiotherapy during the follow-up period. All measurements were repeated after
the completion of the one and two-year follow-up period.
The repeated measures of follow up showed that there was no signiﬁcant difference
among inspiratory and expiratory muscle strength, quadriceps muscle force, and
six-minute walk distance after two-year follow-up (p> 0.05). There was signiﬁcant
difference among FVC, FEV1, and BMI (p< 0.05). In conclusion, respiratory mus-
cle strength, peripheral muscle strength, and functional capacity were preserved by
regular respiratory physiotherapy after two-year while airway obstruction increased
in patients with cystic ﬁbrosis. Body composition also worsened.
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Purpose: Cystic ﬁbrosis patients have reduced exercise tolerance. The purpose of
this study was to investigate chronotropic heart rate response (heart rate reserve
used at peak exercise) to peak bicycle exercise in patients with cystic ﬁbrosis.
Material and Methods: Sixteen patients with cystic ﬁbrosis (age: 13±4 years, 10
M, 6 F, FEV1: 80±27%) participated in the study. Pulmonary function test was
performed. Respiratory muscle strength, quadriceps force, and percent body fat
were measured. A graded bicycle ergometer exercise test and a six minute walk
test were performed. Heart rate, blood pressure, oxygen saturation, dyspnea and
fatigue perception were measured before and after the test.
Results: Nine patients (56%) had lower chronotropic index. Patients with a lower
chronotropic index were signiﬁcantly younger, and reached signiﬁcantly lower
percentage of maximal heart rate during peak bicycle exercise (p< 0.05). There
was no signiﬁcant difference in pulmonary function test values, respiratory and
quadriceps muscle strength, percent body fat and six minute walk distance (p> 0.05)
between patients with low and normal chronotropic index. Chronotropic response
was signiﬁcantly related with Crispin Norman score (p< 0.05).
Conclusion: Chronotropic response to peak exercise is decreased in cystic ﬁbrosis.
It is related to radiological ﬁndings from the view point of Crispin Norman score.
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High frequency chest wall oscillation (HFCWO) is widely used in the United States
and has recently been approved for use in Europe.
Aim: To compare the short-term effects of HFCWO with patients’ usual airway
clearance techniques (ACT) in people with cystic ﬁbrosis admitted to hospital with
an acute infective pulmonary exacerbation.
Methods: A randomised cross-over design, powered to detect a 4-gram difference
in expectorated sputum. Over four days patients received either HFCWO on Days
1 & 3 and their usual ACT on Days 2 & 4 or vice versa. Airway clearance sessions
were 30 minutes twice a day. Expectorated wet weight of sputum, lung function,
perceived efﬁcacy (using a visual analogue scale) and preference were measured.
The difference between usual ACT and HFCWO was estimated using a mixed linear
regression model.
Results: Thirty patients (22 male) were recruited, mean age 29.7 (8.4) years and
mean percent predicted FEV1 37.7(16.5)%. Twenty-nine patients completed the
study. The majority (83%) used the active cycle of breathing techniques or autogenic
drainage as their usual ACT. Signiﬁcantly more sputum was expectorated during
a single treatment session with usual ACT than with HFCWO (p< 0.001). No
signiﬁcant change in FEV1 was observed within or between either regimen. Patients’
usual ACTs scored signiﬁcantly higher for efﬁcacy than HFCWO (mean difference =
14mm; p = 0.002) and seventeen (55%) patients expressed a preference for usual
ACT over HFCWO.
Conclusion: During a ﬁnite treatment period more sputum was cleared using
patients’ usual ACT than HFCWO. HFCWO does not appear to cause any adverse
physiological effects and may inﬂuence adherence.
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Aim: The efﬁciency evaluated of intrapulmonary percussive ventilation (IPV) for
children with cystic ﬁbrosis (CF) for endobronchial secretions drainage.
Materials and Methods: IPV was performed on “IMP2” of “Breas Medical”
(Sweden). Each patient received 20ml of normal saline via the nebulizer component
of the IPV. They also used autogenic drainage (AD) and relaxation. The IPV courses
were over 2−7 days, usually at a frequency of 4 times per day. Lung function was
estimated on the “Jaeger Flow Screen Pro”. All patients were on standard cystic
ﬁbrosis treatment.
Results: IPV received 9 patients with CF, 4−16 years of age, 5 m., 4 f. The
operating pressure was in the range from 1.2 to 2.2 bar, patient pressure to the
inhalation was 15±7.2 mbar or exhalation: 21±6 mbar., attitude percussion to
the inhalation (max): exhalation (min) accordingly 1:2±0.31, frequency percussion
from 128 to 400 c/m, in average 160:261 c/m depending on age. SaO2 increased
signiﬁcantly from 92±3.8% to 96±2.9% (p = 0.03). The quality of sputum increased
dramatically. But there were no signiﬁcant difference in spirometry indexes on IPV
treatment [before: FVC= 81±15.4; FEV1 = 67±11.2; FEV25−75 = 43±9% and after
IPV: FVC= 83±16.9; FEV1 = 66±12.3; FEV25−75 = 48±13.8% (p> 0.05)].
Conclusion: IPV is safe and effective type of physiotherapy for children with cystic
ﬁbrosis. IPV requires further clinical evaluation on a larger number of patients.
